LICENSE AGREEMENT by and between AKCEA THERAPEUTICS, INC. and PFIZER INC.License Agreement • March 2nd, 2020 • Akcea Therapeutics, Inc. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is executed as of October 4, 2019 (the “Execution Date”), by and between Pfizer Inc., a Delaware corporation, having its principal place of business at 235 East 42nd Street, New York, New York 10017 (“Pfizer”), and Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 22 Boston Wharf Road, 9th Floor, Boston, MA 02210 (“Akcea”). Pfizer and Akcea will be referred to herein individually as a “Party” and collectively as the “Parties”.
